105 related articles for article (PubMed ID: 22844128)
1. Evaluation of three definitions of progression-free survival in preoperative cancer therapy (JCOG0801-A).
Nakamura K; Shibata T; Takashima A; Yamamoto S; Fukuda H
Jpn J Clin Oncol; 2012 Oct; 42(10):896-902. PubMed ID: 22844128
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907).
Ando N; Kato H; Igaki H; Shinoda M; Ozawa S; Shimizu H; Nakamura T; Yabusaki H; Aoyama N; Kurita A; Ikeda K; Kanda T; Tsujinaka T; Nakamura K; Fukuda H
Ann Surg Oncol; 2012 Jan; 19(1):68-74. PubMed ID: 21879261
[TBL] [Abstract][Full Text] [Related]
3. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
4. Prediction of prognosis after trimodal therapy in patients with locally advanced squamous cell carcinoma of the oesophagus.
Stahl M; Lehmann N; Walz MK; Stuschke M; Wilke H
Eur J Cancer; 2012 Nov; 48(16):2977-82. PubMed ID: 22503151
[TBL] [Abstract][Full Text] [Related]
5. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.
Felip E; Rosell R; Maestre JA; Rodríguez-Paniagua JM; Morán T; Astudillo J; Alonso G; Borro JM; González-Larriba JL; Torres A; Camps C; Guijarro R; Isla D; Aguiló R; Alberola V; Padilla J; Sánchez-Palencia A; Sánchez JJ; Hermosilla E; Massuti B;
J Clin Oncol; 2010 Jul; 28(19):3138-45. PubMed ID: 20516435
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
9. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials.
Durie BG; Jacobson J; Barlogie B; Crowley J
J Clin Oncol; 2004 May; 22(10):1857-63. PubMed ID: 15111617
[TBL] [Abstract][Full Text] [Related]
10. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
11. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209).
Nagai K; Tsuchiya R; Mori T; Tada H; Ichinose Y; Koike T; Kato H;
J Thorac Cardiovasc Surg; 2003 Feb; 125(2):254-60. PubMed ID: 12579093
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
[TBL] [Abstract][Full Text] [Related]
14. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung.
Suntharalingam M; Paulus R; Edelman MJ; Krasna M; Burrows W; Gore E; Wilson LD; Choy H
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):456-63. PubMed ID: 22543206
[TBL] [Abstract][Full Text] [Related]
15. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
16. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
Panici PB; Maggioni A; Hacker N; Landoni F; Ackermann S; Campagnutta E; Tamussino K; Winter R; Pellegrino A; Greggi S; Angioli R; Manci N; Scambia G; Dell'Anna T; Fossati R; Floriani I; Rossi RS; Grassi R; Favalli G; Raspagliesi F; Giannarelli D; Martella L; Mangioni C
J Natl Cancer Inst; 2005 Apr; 97(8):560-6. PubMed ID: 15840878
[TBL] [Abstract][Full Text] [Related]
17. When you look matters: the effect of assessment schedule on progression-free survival.
Panageas KS; Ben-Porat L; Dickler MN; Chapman PB; Schrag D
J Natl Cancer Inst; 2007 Mar; 99(6):428-32. PubMed ID: 17374832
[TBL] [Abstract][Full Text] [Related]
18. Designing phase II studies in cancer with time-to-event endpoints.
Owzar K; Jung SH
Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
[TBL] [Abstract][Full Text] [Related]
19. Preoperative concurrent chemotherapy and radiation therapy followed by surgery for esophageal cancer.
Yano M; Inoue M; Shiozaki H
Ann Thorac Cardiovasc Surg; 2002 Jun; 8(3):123-30. PubMed ID: 12472392
[TBL] [Abstract][Full Text] [Related]
20. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
